Lupin’s wholly owned subsidiary in US — Lupin Pharmaceuticals — has partnered with the American Sexual Health Association (ASHA) and the National Association of Nurse Practitioners in Women’s Health (NPWH) to conduct a two-pronged national online survey among women who have been diagnosed with bacterial vaginosis (BV) and healthcare providers (HCPs) who treat women with … Read more
Lupin has received tentative approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Sunovion Pharmaceuticals Inc.’s (Sunovion) Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. Lupin’s Lurasidone … Read more
Lupin has launched Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Ointment USP 0.05% had annual sales of around $93.4 million in the US (IQVIA MAT June 2018). The company’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals … Read more
